These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
259 related articles for article (PubMed ID: 29466886)
21. Targeted multiplexed selected reaction monitoring analysis evaluates protein expression changes of molecular risk factors for major psychiatric disorders. Wesseling H; Gottschalk MG; Bahn S Int J Neuropsychopharmacol; 2014 Oct; 18(1):. PubMed ID: 25539505 [TBL] [Abstract][Full Text] [Related]
22. Identifying Plasma Biomarkers with high specificity for major depressive disorder: A multi-level proteomics study. Shi Y; Song R; Wang L; Qi Y; Zhang H; Zhu J; Zhang X; Tang X; Zhan Q; Zhao Y; Swaab DF; Bao AM; Zhang Z J Affect Disord; 2020 Dec; 277():620-630. PubMed ID: 32905914 [TBL] [Abstract][Full Text] [Related]
23. Discovery of serum protein biomarkers in drug-free patients with major depressive disorder. Lee MY; Kim EY; Kim SH; Cho KC; Ha K; Kim KP; Ahn YM Prog Neuropsychopharmacol Biol Psychiatry; 2016 Aug; 69():60-8. PubMed ID: 27105922 [TBL] [Abstract][Full Text] [Related]
24. Is depression associated with increased oxidative stress? A systematic review and meta-analysis. Black CN; Bot M; Scheffer PG; Cuijpers P; Penninx BW Psychoneuroendocrinology; 2015 Jan; 51():164-75. PubMed ID: 25462890 [TBL] [Abstract][Full Text] [Related]
25. Toward an integrated pipeline for protein biomarker development. Drabovich AP; Martínez-Morillo E; Diamandis EP Biochim Biophys Acta; 2015 Jun; 1854(6):677-86. PubMed ID: 25218201 [TBL] [Abstract][Full Text] [Related]
26. Reverse cholesterol transport and lipid peroxidation biomarkers in major depression and bipolar disorder: A systematic review and meta-analysis. Almulla AF; Thipakorn Y; Algon AAA; Tunvirachaisakul C; Al-Hakeim HK; Maes M Brain Behav Immun; 2023 Oct; 113():374-388. PubMed ID: 37557967 [TBL] [Abstract][Full Text] [Related]
27. Undiagnosed bipolar disorder in patients treated for major depression in China. Hu C; Xiang YT; Ungvari GS; Dickerson FB; Kilbourne AM; Si TM; Fang YR; Lu Z; Yang HC; Chiu HF; Lai KY; Hu J; Chen ZY; Huang Y; Sun J; Wang XP; Li HC; Zhang JB; Wang G J Affect Disord; 2012 Oct; 140(2):181-6. PubMed ID: 22397888 [TBL] [Abstract][Full Text] [Related]
28. The promise of biomarkers in diagnosing major depression in primary care: the present and future. Redei EE; Mehta NS Curr Psychiatry Rep; 2015 Aug; 17(8):601. PubMed ID: 26081681 [TBL] [Abstract][Full Text] [Related]
29. Proteomic-based biomarker discovery for development of next generation diagnostics. Khalilpour A; Kilic T; Khalilpour S; Álvarez MM; Yazdi IK Appl Microbiol Biotechnol; 2017 Jan; 101(2):475-491. PubMed ID: 28013407 [TBL] [Abstract][Full Text] [Related]
30. Proteomics strategies for bipolar disorder evaluation: From sample preparation to validation. de Jesus JR; Pessôa GS; Sussulini A; Martínez JLC; Arruda MAZ J Proteomics; 2016 Aug; 145():187-196. PubMed ID: 27113133 [TBL] [Abstract][Full Text] [Related]
31. Systemic sclerosis biomarkers discovered using mass-spectrometry-based proteomics: a systematic review. Bălănescu P; Lădaru A; Bălănescu E; Băicuş C; Dan GA Biomarkers; 2014 Aug; 19(5):345-55. PubMed ID: 24831309 [TBL] [Abstract][Full Text] [Related]
32. The Discovery of Clinically Applicable Biomarkers for Bipolar Disorder: A Review of Candidate and Proteomic Approaches. Muneer A Chonnam Med J; 2020 Sep; 56(3):166-179. PubMed ID: 33014755 [TBL] [Abstract][Full Text] [Related]
33. Biomarkers of systemic lupus erythematosus identified using mass spectrometry-based proteomics: a systematic review. Nicolaou O; Kousios A; Hadjisavvas A; Lauwerys B; Sokratous K; Kyriacou K J Cell Mol Med; 2017 May; 21(5):993-1012. PubMed ID: 27878954 [TBL] [Abstract][Full Text] [Related]
34. A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression. Goldsmith DR; Rapaport MH; Miller BJ Mol Psychiatry; 2016 Dec; 21(12):1696-1709. PubMed ID: 26903267 [TBL] [Abstract][Full Text] [Related]
35. Prevalence and humanistic impact of potential misdiagnosis of bipolar disorder among patients with major depressive disorder in a commercially insured population. Kamat SA; Rajagopalan K; Pethick N; Willey V; Bullano M; Hassan M J Manag Care Pharm; 2008 Sep; 14(7):631-42. PubMed ID: 18774873 [TBL] [Abstract][Full Text] [Related]
36. Mass spectrometry-based proteomic quest for diabetes biomarkers. Shao S; Guo T; Aebersold R Biochim Biophys Acta; 2015 Jun; 1854(6):519-27. PubMed ID: 25556002 [TBL] [Abstract][Full Text] [Related]
37. Proteomic enrichment analysis of psychotic and affective disorders reveals common signatures in presynaptic glutamatergic signaling and energy metabolism. Gottschalk MG; Wesseling H; Guest PC; Bahn S Int J Neuropsychopharmacol; 2014 Oct; 18(2):. PubMed ID: 25609598 [TBL] [Abstract][Full Text] [Related]
38. Functional versus syndromal recovery in patients with major depressive disorder and bipolar disorder. van der Voort TY; Seldenrijk A; van Meijel B; Goossens PJ; Beekman AT; Penninx BW; Kupka RW J Clin Psychiatry; 2015 Jun; 76(6):e809-14. PubMed ID: 26132690 [TBL] [Abstract][Full Text] [Related]
39. Targeted and Untargeted Proteomics Approaches in Biomarker Development. Sobsey CA; Ibrahim S; Richard VR; Gaspar V; Mitsa G; Lacasse V; Zahedi RP; Batist G; Borchers CH Proteomics; 2020 May; 20(9):e1900029. PubMed ID: 31729135 [TBL] [Abstract][Full Text] [Related]
40. Analytical approaches for lipidomics and its potential applications in neuropsychiatric disorders. Sethi S; Hayashi MA; Sussulini A; Tasic L; Brietzke E World J Biol Psychiatry; 2017 Oct; 18(7):506-520. PubMed ID: 26555297 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]